Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (NET) treated initially with Lanreotide AG and methods of further treatment approaches after progression real-world data

#3833

Introduction: .

Aim(s): Evaluation of PFS & OS in patients with advanced pancreatic (panNET) treated initially Lanreotide AG and assessed further therapy approaches after relapse of 1-st line.

Materials and methods: Retrospective analysis including 580 pts with panNETG1/G2. Study group 100, responses based on RECIST. Clinical, biochemical & AEs assessed after each of 4 wks PFS and OS, utilized standard Kaplan–Meier estimator, Cox proportional model used to assess significancy of differences between predictor factors.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślicka A, Bednarczuk T, Osowiecka K, Słoniewska A,

Keywords: advanced NET, non-resectable pancreatic neuroendocrine tumor, Lanreotide therapy, real word data set,